A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella

Pediatr Infect Dis J. 2009 Jul;28(7):653-5. doi: 10.1097/INF.0b013e3181998f06.


Herpes zoster, may be severe and recurrent in HIV-infected children. We determined the safety and immunogenicity of live attenuated varicella-zoster virus (VZV) vaccine in 46 HIV-infected children who had experienced varicella. There were no serious adverse events. Two years after vaccination 82% of subjects remained VZV-antibody positive and 60% had VZV-specific cell-mediated immunity. No child developed herpes zoster.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II

MeSH terms

  • Antibodies, Viral / blood
  • Chickenpox Vaccine / adverse effects*
  • Chickenpox Vaccine / immunology*
  • Child
  • HIV Infections / immunology*
  • Herpes Zoster / prevention & control*
  • Herpesvirus 3, Human / immunology*
  • Humans
  • Immunization, Secondary / methods*
  • Longitudinal Studies
  • Male
  • T-Lymphocytes / immunology
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology


  • Antibodies, Viral
  • Chickenpox Vaccine
  • Vaccines, Attenuated